title: Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
abstract: OBJECTIVE
  The prognostic significance of the rate of decline of the serum tumor marker alpha-fetoprotein (AFP) and human chorionic gonadotrophin (HCG) during the first two cycles of chemotherapy in germ cell tumor (GCT) patients was initially reported by us, but its value has been debated. We re-examined this issue in the context of the International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification system and investigated the role of including in the analysis patients whose markers normalized early.
  
  
  METHODS
  One hundred eighty-nine GCT patients with elevated AFP/HCG marker values treated with platinum-based chemotherapy between 1986 and 1998 were included in this analysis. Patients were classified as good, intermediate, or poor risk by the IGCCCG criteria and as having satisfactory or unsatisfactory marker decline. Risk and marker decline were correlated with response, event-free survival, and overall survival.
  
  
  RESULTS
  Satisfactory marker decline predicted improved complete response (CR) proportion and event-free and overall survival (P <.0001). The CR proportion, 2-year event-free, and 2-year overall survival rates for patients with a satisfactory and unsatisfactory marker decline were 92% versus 62%, 91% versus 69%, and 95% versus 72%, respectively. Marker decline remained a significant variable for all three end points when adjusted for risk (P <.01) with the outcome differences most pronounced in the poor-risk group.
  
  
  CONCLUSIONS
  The rate of marker decline during chemotherapy has prognostic value independent of risk and may play a significant role in the management of poor-risk patients. It is appropriate to include patients whose markers normalized early.
authors.affiliation: Department of Epidemiology and Biostatistics and the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. mazumdar@biost.mskcc.org
authors.forename: M
authors.initials: M
authors.lastname: Mazumdar
authors.forename: D F
authors.initials: DF
authors.lastname: Bajorin
authors.forename: J
authors.initials: J
authors.lastname: Bacik
authors.forename: G
authors.initials: G
authors.lastname: Higgins
authors.forename: R J
authors.initials: RJ
authors.lastname: Motzer
authors.forename: G J
authors.initials: GJ
authors.lastname: Bosl
mesh_terms: D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D006063:Chorionic Gonadotropin / Q000097:blood*; D018237:Germinoma / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D008479:Mediastinal Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D011379:Prognosis; D012186:Retroperitoneal Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D013736:Testicular Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D000509:alpha-Fetoproteins / Q000032:analysis*
chemical_list: D014408:Biomarkers, Tumor; D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins